Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Wick

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Neuropathology and Applied Neurobiology|May 12, 2007
De novo erythropoietin receptor (EPO-R) expression in human neoplastic glial cells decreases with grade of malignancy but is favourably associated with patient survivalM Mittelbronn, D Capper, B Bunz, et al.
ESMO Open|October 20, 2023
Leptomeningeal metastasis from solid tumours: EANO-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upE Le Rhun, M Weller, M van den Bent, et al.
Oncogene|May 8, 2012
Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatmentM Weiler, P-N Pfenning, A-L Thiepold, et al.
European Journal of Neurology|August 20, 2010
Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task ForceR Soffietti, B G Baumert, L Bello, et al.
BMC Cancer|June 12, 2022
Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trialA Wick, A Sander, M Koch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2020
Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-upP Roth, A Pace, E Le Rhun, et al.
Acta Neuropathologica Communications|April 27, 2019
DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and developmentH Binder, E Willscher, H Loeffler-Wirth, et al.
Neuropathology and Applied Neurobiology|October 17, 2018
Integrated molecular characterization of IDH-mutant glioblastomasA Korshunov, B Casalini, L Chavez, et al.
Journal of Neuropathology and Experimental Neurology|June 13, 2000
Comprehensive allelotype and genetic anaysis of 466 human nervous system tumorsA von Deimling, R Fimmers, M C Schmidt, et al.
Journal of Neuro-Oncology|January 8, 2014
NDRG1 prognosticates the natural course of disease in WHO grade II gliomaJ Blaes, M Weiler, F Sahm, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Neuropathology and Applied Neurobiology|May 12, 2007
De novo erythropoietin receptor (EPO-R) expression in human neoplastic glial cells decreases with grade of malignancy but is favourably associated with patient survivalM Mittelbronn, D Capper, B Bunz, et al.
ESMO Open|October 20, 2023
Leptomeningeal metastasis from solid tumours: EANO-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upE Le Rhun, M Weller, M van den Bent, et al.
Oncogene|May 8, 2012
Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatmentM Weiler, P-N Pfenning, A-L Thiepold, et al.
European Journal of Neurology|August 20, 2010
Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task ForceR Soffietti, B G Baumert, L Bello, et al.
BMC Cancer|June 12, 2022
Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trialA Wick, A Sander, M Koch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2020
Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-upP Roth, A Pace, E Le Rhun, et al.
Acta Neuropathologica Communications|April 27, 2019
DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and developmentH Binder, E Willscher, H Loeffler-Wirth, et al.
Neuropathology and Applied Neurobiology|October 17, 2018
Integrated molecular characterization of IDH-mutant glioblastomasA Korshunov, B Casalini, L Chavez, et al.
Journal of Neuropathology and Experimental Neurology|June 13, 2000
Comprehensive allelotype and genetic anaysis of 466 human nervous system tumorsA von Deimling, R Fimmers, M C Schmidt, et al.
Journal of Neuro-Oncology|January 8, 2014
NDRG1 prognosticates the natural course of disease in WHO grade II gliomaJ Blaes, M Weiler, F Sahm, et al.
Pageof 8